Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
EDITORIAL
Νew treatments in Cystic Fibrosis
1
Assistant Professor in Pulmonary Medicine, Pulmonary Department,
Aristotle University of Thessaloniki,
“G. Papanikolaou” Hospital, Exohi,
Thessaloniki, Greece
2
Associate Professor in Pulmonary Medicine and Infectious Diseases, Respiratory Infections Unit and Adult Cystic Fibrosis Center, Pulmonary Department, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, Exohi, Thessaloniki, Greece
Corresponding author
Ioannis Kioumis
Pulmonary Department, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, 57010 Exohi, Thessaloniki, Greece
Pulmonary Department, Aristotle University of Thessaloniki, “G. Papanikolaou” Hospital, 57010 Exohi, Thessaloniki, Greece
Pneumon 2016;29(4):278-281
KEYWORDS
REFERENCES (39)
1.
Lane MA, Doe SJ. A new era in the treatment of cystic fibrosis. Clin Med 2014;14:76-8.
2.
Bosch B, De Boeck KD. Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell. Eur J Pediatr 2016;175:1-8.
3.
Quintana-Gallego E, Delgado-Pecellín I, Calero Acuña C. CFTR protein repair therapy in cystic fibrosis. Arch Bronconeumol 2014;50:146-50.
4.
Cystic Fibrosis Foundation Patient Registry. 2014 Annual Data Report. Bethesda, Maryland, 2015.
5.
European Cystic Fibrosis Society Patient Registry. Annual data report (year 2013). Version 02.2016.
6.
Elborn JS, Bell CS, Madge SL et al. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. Eur Respir J 2016;47:420-8.
8.
Toronto, Cystic Fibrosis Centre at the Hospital for Sick Children. 2015, Cystic fibrosis mutation database. Retrieved from: http://www.genet.sickkids.on.c....
9.
Veit G, Avramescu RG, Chiang AN et al. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 2016;27:424-33.
10.
Bhalla V, Hallows KR. Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol 2008;19:1845-54.
11.
De Boeck K, Zolinb A, Cuppens H, Olesend HV, Vivianib L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibrosis 2014;13:403–9.
12.
US CF Foundation, Johns Hopkins University, the Hospital for Sick Children. The clinical and functional translation of CFTR (CFTR2). 2011. (http://cftr2.org).
13.
Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059–65.
14.
Castellani S, Conese M. Lentiviral vectors and cystic fibrosis gene therapy. Viruses 2010;2:395–412.
15.
Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997;71:5932–41.
16.
Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-9.
17.
Mackenzie T, Gifford A, Sabadosa K, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. Ann Intern Med 2014;161:233–41.
18.
Kuk K, Taylor-Cousar J. Lumcaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Ther Adv Respir Dis 2015;9:313-26.
19.
Accurso F, Rowe S, Clancy J et al. Effect of Vx-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363:1991–2003.
20.
Ramsey B, Davies J, McElvaney N et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663–72.
21.
Davies J, Wainwright C, Canny G et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013;187:1219–25.
22.
Borowitz D, Lubarsky B, Wilschanski M et al. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor. Dig Dis Sci 2016;61:198-207.
23.
Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014;190:175–84.
24.
Boyle M, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013;1:158–63.
25.
De Boeck K, Munck A, Walker S et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 2014;13:674–80.
26.
Flume P, Liou T, Borowitz D et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del CFTR mutation. Chest 2012;142:718–24.
27.
Clancy J, Rowe S, Accurso F, et al. Results of a phase IIa study of VX-809, an investigational CFTR Corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12–8.
28.
Boyle M, Bell S, Konstan, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014;2: 527–38.
29.
Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;16:220-31.
30.
Rehman A, Ul-Ain Baloch N, Janachi IA. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:1783.
31.
Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996;2:467-69.
32.
Clancy JP, Bebök Z, Ruiz F, King C, Jones J, Walker L. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001;163:1683-92.
33.
Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, Pierrot S. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007;5:5.
34.
Aurino S, Nigro V. Readthrough strategies for stop codons in Duchenne muscular dystrophy. Acta Myol 206;25:5–12.
35.
Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010;182:1262–72.
36.
Clancy JP, Konstan MW, Rowe SM, et al. A Phase 2 study of PTC124 in cystic fibrosis patients harboring premature stop mutations. Pediatr Pulmonol 2006;40(Suppl29):301.
37.
Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719–27.
38.
Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011;38:59–69.
39.
Kerem E, Konstan MW, De Boeck K, et al. A randomized placebocontrolled trail of ataluren for the treatment of nonsense mutation cystic fibrosis. Lancet Respir Med 2014;2:539-47.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
